Legend Biotech (LEGN) EBIT (2019 - 2026)
Legend Biotech's (LEGN) quarterly EBIT came in at -$49.8 million in Q1 2026, up 3.68% YoY from -$48.0 million in Q1 2025, and down 152.79% on a QoQ basis from -$19.7 million in Q4 2025.
Legend Biotech (LEGN) EBIT (2019 - 2026) Analysis & Trends
Legend Biotech (LEGN) has 8 years of EBIT data on file, last reported at -$49.8 million in Q1 2026.
- Quarterly EBIT rose 3.68% year-over-year to -$49.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $178.1 million (up 102.9% YoY) and the FY2025 annual result came in at -$136.5 million, up 55.9% from the prior year.
- EBIT declined to -$49.8 million in Q1 2026, from -$19.7 million in the prior quarter.
- In the past five years, EBIT ranged from a high of $79.4 billion in Q4 2023 to a low of -$189.3 million in Q2 2022.
- A 5-year average of $4.7 billion and a median of $107.8 million in 2023 frame the typical range for EBIT.
- Annual changes were most pronounced in 2022 — EBIT plunged 58501.13% — and 2023, when it surged 70754.09%.
- Tracing LEGN's EBIT over 5 years: stood at $112.1 million in 2022, then surged by 70754.09% to $79.4 billion in 2023, then sank by 100.1% to -$79.3 million in 2024, then soared by 75.16% to -$19.7 million in 2025, then sank by 152.79% to -$49.8 million in 2026.
- The last three EBIT figures came in at -$49.8 million (Q1 2026), -$19.7 million (Q4 2025), and -$43.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Legend Biotech | 3.95 Bn | 3.27 Bn | 251.50 Mn | 57.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 57.70 Mn |
| Mar 31, 2026 | -49.80 Mn |
| Dec 31, 2025 | -19.70 Mn |
| Sep 30, 2025 | -43.45 Mn |
| Jun 30, 2025 | 291.08 Mn |
| Mar 31, 2025 | -51.70 Mn |
| Dec 31, 2024 | -79.30 Mn |
| Sep 30, 2024 | -70.36 Mn |
| Jun 30, 2024 | 289.15 Mn |
| Mar 31, 2024 | 177.78 Mn |
| Dec 31, 2023 | 79.43 Bn |
| Sep 30, 2023 | 176.49 Mn |
| Jun 30, 2023 | 164.20 Mn |
| Mar 31, 2023 | 107.82 Mn |
| Dec 31, 2022 | 112.11 Mn |
| Sep 30, 2022 | 129.66 Mn |
| Jun 30, 2022 | -189.34 Mn |
| Mar 31, 2022 | -33.17 Mn |
| Dec 31, 2021 | -88.94 Mn |
| Sep 30, 2021 | -124.96 Mn |